Peroxiredoxin III : a candidate for drug resistance to chemotherapy : a thesis presented in partial fulfillment of the requirements for the degree of Master of Science in Biochemistry at Massey University, Palmerston North, New Zealand by Aalderink, Miranda
Copyright is owned by the Author of the thesis.  Permission is given for 
a copy to be downloaded by an individual for the purpose of research and 
private study only.  The thesis may not be reproduced elsewhere without 
the permission of the Author. 
 
Peroxiredoxin III: A candidate for 
drug resistance to chemotherapy 
A thes is presented in parti al fulfillm ent of the requirements fo r the degree of 
Master of Science in Biochemistry at Massey University, 
Palmerston orth , ew Zealand . 
Miranda Aalderink 
2008 
Acknowledgements 
I wou ld like to express my thanks to Dr. Kathryn Stowell, who was an exceptional 
supervisor. Thanks for always making time to talk to me, always being approachable and 
always encouraging me. Thanks also for allowing me to make my own mistakes without 
letting me get too far off track. Thanks also to Dr. Richard Isaacs for your help in 
organizing patients to take part in this study. 
Words can not express how grateful I am for the support of my family and friends . Thank 
you to my Mum and Dad for the encouragement, support, and patience, and for always 
taking the time to listen to me, even when you didn ' t understand what I was talking 
about. Thank you to Jeroen for being the best brother and friend a girl could have . Thank 
you to Kelly Gilchrist for always being there , always believing in me, and always 
convincing me to believe in myself whenever things got difficult. 
Thank you to everyone in the Twilite Zone for making being in the lab so much fun. 
Special thanks to Natisha Magan, for all the help , encouragement and entertainment over 
the past two years, and to Rebecca Hole, Hilbert Grievink, Lili Rhodes and Robyn 
Marston for always being available to give advice or provide entertaining conversation. 
Thank you to the amazing women who took part in this study during an incredibly trying 
time. Thank you also to Massey University for the financial support. 
To my Mo - this one 's for you. 
11 
Abstract 
The development of drug resistance to chemotherapeutic drugs is a serious obstacle in the 
successful treatment of cancer. New cancer drugs are continually being developed with 
the goal of increasing the effectiveness of chemotherapy. However, new mechanisms of 
drug resistance are also continually being identified. Understanding the mechanisms of 
drug resistance is a vital step in identifying new drug targets which may prevent or 
reduce the development of drug resistance. A recent unpublished study identified 
peroxiredoxin III (prx Ill) as being up-regulated in breast cancer cells in culture 
following exposure to the commonly used anti-cancer drug doxorubicin. 
Doxorubicin and the almost identical drug epirubicin have multiple mechanisms of 
activity. One function of these drugs is to increase intracellular hydrogen peroxide (H20 2) 
concentrations to induce cell death. As prx Ill is a mitochondrial protein which reduces 
H20 2, it has been suggested that increased expression of prx Ill may contribute to the 
development of drug resistance to doxorubicin or epirubicin. However, before such a role 
for prx Ill in the development of drug resistance can be further investigated, prx Ill 
expression needs to be examined in patients undergoing chemotherapy. 
The aim of this study was to examme prx Ill expression 111 the white blood cells of 
patients undergoing chemotherapy with epirubicin, and in healthy control subjects. 
Additionally, as the activity of a number of peroxiredoxins has been shown to be 
modulated through the formation of complexes and over-oxidation, complex formation 
and over-oxidation in response to treatment with doxorubicin or epirubicin was also 
examined. The results of this study could identify a new target for preventing or reducing 
the development of drug resistance. While the sample sizes were too small to draw 
conclusions, some patients showed a change in the expression of peroxiredoxin III 
following chemotherapy with epirubicin, suggesting that further investigation into the 
expression of peroxiredoxin III following chemotherapy would be worthwhile. 
Ill 
2-cys 
2DE 
ABC 
APS 
ARE 
ATP 
bp 
BSA 
cDNA 
c-Myc 
cs 
CT 
DCF 
DCFH-DA 
DEPC 
DMSO 
DNA 
dNTP 
Dox 
DTT 
EDTA 
EGF 
EMSA 
Epi 
ER 
ERRa 
FBS 
Gl 
Abbreviations 
2-cysteine 
Two-dimensional electrophoresis 
A IP-binding cassette transporter 
Ammonium persulfate 
Antioxidant response element 
Adenosine triphosphate 
Base pairs (DNA) 
Bovine serum albumin 
Complimentary DNA 
Proto-oncogene 
Citrate synthase 
Threshold cycle 
Dichlorofluorescein 
2 ' , 7' -dichlorofluorescin di acetate 
Diethylpyrocarbonate 
Dimethyl sulfoxide 
Deoxyribose nucleic acid 
Deoxynucleoside triphosphate (dATP, dTTP, dGTP, dCTP) 
Doxorubicin 
Dithiothreitol 
Ethylene diamine tetra-acetic acid 
Epidermal growth factor 
Electrophoretic mobility shift assay 
Epirubicin 
Estrogen receptor 
Estrogen-related receptor a 
Fetal bovine serum 
Gap 1 
IV 
HeLa 
Hi95 
HRP 
IEF 
IPG 
K562 
kDa 
MCFlOA 
MCF7 
MEM 
mRNA 
NADPH 
NFKB 
02·-
p53 
PA26 
PAGE 
PBS 
PCR 
PDGF 
Pen-Strep 
PGC-lu 
P-gp 
pl 
Prx 
Prx III 
prxs 
PVDF 
RBC 
RIPA 
RNA 
Human cervical carinoma cells 
Human sestrin 
Horseradish peroxidase 
Isoelectric focusing 
Immobilised pH gradient 
Human leukemia cell line 
Kilodaltons 
Normal human breast epithelial cell line 
Human breast carcinoma cell line 
Minimum essential medium 
Messenger RN A 
Nicotinamide adenine dinucleotide phosphate 
Nuclear factor kappa B 
Superoxide anion 
Tumour suppressor protein 
Human sestrin 
Polyacrylamide gel electrophoresis 
Phosphate buffered saline 
Polymerase chain reaction 
Platelet derived growth factor 
Penicillin-streptomycin 
Peroxisome proliferator-activated receptor y coactivator-1 a 
P-glycoprotein 
Isoelectric point 
Peroxiredoxin 
Peroxiredoxin Ill 
Peroxiredoxins 
Polyvinylidine fluoride 
Red blood cell 
Radio-immuno precipitation 
Ribonucleic acid 
V 
RNase 
ROS 
rpm 
rRNA 
RT 
sos 
Srxl 
TAE 
TBST 
TEMED 
TEN 
Thr 
TNF-a 
tRNA 
TrypLE 
UV 
WBC 
Ribonuclease 
Reactive oxygen species 
revolutions per minute 
Ribosomal RNA 
Reverse transcription 
Sodium dodecyl sulfate 
Sulfiredoxin 
Tris acetate EDT A buffer 
Tris-buffered saline-TWEEN 20 
N ,N ,N',N'-Tetramethylethylenediamine 
Tris-EDTA-Sodium chloride buffer 
Threonine 
Tumour necrosis factor a 
Transfer RNA 
Express stable trypsin-like enzyme plus phenol red 
Ultraviolet 
White blood cell 
Vl 
List of Figures 
Figure 1. 1: Mechanism of H2O2 reduction by 2-cys peroxiredoxins 
Figure 3.1: Outline of the principles ofreal time PCR 
Figure 3.2: Primer sequences 
Figure 3.3: ~-actin and peroxiredoxin llI PCR products 
Figure 3.4 Digestion of peroxiredoxin III product with SphI 
Figure 3.5: Alignment of PCR product sequence and prx Ill mRNA 
sequence 
Figure 3.6: Low primer concentration results in a shift in amplification 
curves 
Figure 3.7: Western blot results for all control samples 
Figure 3.8: Western blot results for all patient samples 
Figure 3.9: Longer exposures results showed higher molecular weight 
bands were detected by the ~-actin antibody 
Figure 4.1: Native PAGE and western blotting of MCF7 extracts 
Figure 4.2: Representative western blot results for patient samples 
Figure 4.3: Representative western blot results for control samples 
Figure 5.1: Outline of two-dimensional electrophoresis experiments 
Figure 5.2: Over-oxidation of peroxiredoxin Ill 
Figure 5.3: Exposure of MCF7 cells to doxorubicin did not result in 
peroxiredoxin lll over-oxidation 
Figure 6.1: Overview of a possible explanation of prx lll complex 
formation 
Vil 
Page number 
7 
40 
42 
44 
45 
46 
48 
56 
57 
58 
64 
67 
68 
71 
73 
75 
83 
List of Tables 
Table 2.1: Resolving and stacking gel solutions for SOS-PAGE 
Table 2.2: Resolving and stacking gel solutions for native PAGE 
Table 2.3: Real time PCR components required for one reaction 
Table 2.4: The LightCycler 480 cycle programme 
Table 3.1: Efficiency values determined from ten individual 
standard curves 
Table 3.2: Peroxiredoxin Ill fold changes calculated for patients 
Table 3.3: Peroxiredoxin Ill fold changes calculated for all control 
samples 
Vlll 
Page number 
23 
29 
35 
35 
50 
52 
53 
Table of Contents 
Acknowledgements ..................................... .............. .... ... ............ ..................................... ii 
Abstract .................................................................... ........... .............................................. iii 
Abbreviations ................................................................................................................... iv 
List of Figures .................................................................................................................. vii 
List of Tables .............. .................. .................................................................................. viii 
Table of Contents .............. ................ .. ........... .... .............................................................. ix 
Chapter 1: Introduction .. ...................................................................................... ....... 1 
1.1 Cancer ... .... .... ....... ........................... ... ..... .. ................ ........... ............................... 1 
1.2 Mechanisms of drug resistance ... ... .. ....... .. ................. .......... .... .. .. .. .... ... ...... ........ 3 
1.3 Searching for new mechanisms of resistance ...... ............. ....... ......................... .. 4 
1.4 Peroxiredoxins ....... ................. .......... ........ ... ... ........... .. ... ......... .......... ........... ..... . 5 
1. 5 Peroxiredoxins and Reactive Oxygen Species ........... ....... .. ................ ..... ........ ... 7 
1.6 Peroxiredoxins as molecular chaperones ..... ... ......... ........ ...... ....... ..................... 9 
1. 7 Regeneration of active peroxiredoxin .... .... .... ...... ..... ....... ... ... ... ........................ 11 
1.8 Peroxiredoxins and disease ...... .. ........................ ...... ..... .............. ..................... 11 
1.9 Peroxiredoxin l/1. ....... ...... .... ............. .. ... ...... ......... ... ...... ........ ................... ..... .. . 12 
1.10 Research aims .............................. ........ ...................... ................. ..... ... .............. 15 
Chapter 2: Materials and methods ........................................................................... 17 
2. 1 Materials .... .... ............ ....... ... .... ................ ........... ...... .. ... ...... ... ........... .. ........ ... .. 17 
2.2 Mammalian cell culture ............ ... ........... ... ............. ..... ... ... ... ....... ................ ..... 19 
2.2. I Media .................. .......................... ....... ................................... ............ .......... 19 
2.2.2 Starting cells from frozen stocks ..... ... .... ... .. ... .. .... .......... ............... ......... .. ..... 19 
2.2.3 Passage of cells ....... .... ... ... .. ..... ..... .. .. ........... ... .... .... ................... ... ... ....... ...... 19 
2.2. 4 Freezing of cells ... ....... .. ................ ......................................... .... .. .. ........ ..... .. 20 
2.2.5 Exposure of cells to doxorubicin .. .................. ...... ................. ....... ... ..... .. ..... .. 20 
2.2.6 Exposure of cells to oxidative stress ... ... ... ............... .... .......... .. ..................... 20 
2.3 Isolation of white blood cells ................. ... ... ........ .... ..... .. ... .............................. . 20 
2. 4 Protein extraction and quantification ....... ... .... ... .. .. .... .. ....... ... .... ........ ...... ....... . 21 
IX 
2.4.1 
2.4.2 
2.4.3 
2.5 
2.5.1 
2.5.2 
2.5.3 
2.6 
2.6. 1 
2.6.2 
2.6.3 
2.7 
2.7.1 
2.7.2 
2.7.3 
2.7.4 
2.7.5 
2.8 
2.8.1 
2.8.2 
2.9 
2.9. 1 
2.9.2 
2. 10 
2.11 
2.11.1 
2. 11.2 
2.11.3 
2.11.4 
2. 11 .5 
2.12 
2. 12.1 
2.12.2 
Preparation of cells grown in mono/ayer for protein extraction .................. 21 
Extraction of total cellular protein ....... ...... ..... ..... ............... .... .. ...... ....... ...... 21 
Quantification of protein extracts .. .... .............. .............................. .. ............. 22 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) .. .... 22 
Casting of 10% SDS-PAGE gels ................. ............ ... ........... ....... ...... ........... 23 
SDS-PAGE ......... .... ......................... .................... .......... ...... .......... ................ 24 
Coomassie staining of polyacrylamide gels .................................................. 24 
Immunoblotting ....... ............. .... ....... .. ..... .... ..... .. ... ... .... .. ........ ..... .......... ..... ... ..... 24 
Transfer of proteins to PVDF membrane ................... ..... ........... .................. 25 
Immunoblotting ............................ .............. ...... ........................ ...... ... ............ 25 
Stripping of PVDF membranes .................................................... ........... ...... 26 
Two-dimensional electrophoresis ................. ......... ............. .............. ........ ........ 26 
Preparation of protein sample for 2DE ........................................ ........ ........ 26 
Isoelectricfocusing ........ .... ............. ....... ..................... ... ......... .......... ............ 27 
Polyacry lamide gel casting/or 2DE .................. .......... ...... .......................... . 27 
Second dimension: SDS-PAGE ............. .. .......... ........... .... ....... ...... .. ....... .... ... 28 
1mmunoblotting of 2DE gel ....... .. ... .................... .. ........ ... ... ........................... 28 
Native polyacrylamide gel electrophoresis ................................. .. .................... 28 
Casting of native PAGE gels .. ...... ...... ...... .............. ...... .. .......... .. ... .............. .. 28 
Native PAGE ......... .. ........... ........... ....... ............... ...... .... ......................... ...... . 29 
Extraction of RNA ................................................................. ..................... .. ..... 30 
Diethylpyrocarbonate treatment of tubes, tips and water ........ .......... .......... 30 
Extraction of RNA ......................................................................................... 30 
Complimentary DNA synthesis .......... ........................... ....... ............................ . 31 
Polymerase chain reaction (PCR) ....... .......................... .... ............................... 32 
Reaction set up ................. ...... ....... .. .............................................................. 32 
Agarose gel electrophoresis ................................ .................................... ...... 33 
Purification of PCR product for sequencing ............... .. ............................... 33 
DNA sequence analysis ... .. .............................. ...... ........... .. ........................... 34 
Restriction endonuclease digests .............................. ..... ............... .. .............. 34 
Real time PCR ................................ ............................... ... .. .......... ........... ...... .. .. 34 
Setting up the basic reaction ......................................................................... 34 
Determination of optimal primer concentrations ......................................... 36 
X 
2. 12.4 
2. 12.5 
2.13 
2.14 
Determination of primer efficiency .... ................ ....... .. .... .... ... ...... ... .. .... ........ 36 
Calculation of relative expression levels ....... ...... ... .. ....... ... ... ... ... .. ............... 3 7 
Statistical Analysis ....... ........... .. ................... ... .. .................. ................... ........... 3 7 
Ethics Approval. ............ .................. .................. .......... .. .. .. .. ................. .. ..... ...... 3 7 
Chapter 3: Expression of peroxiredoxin Ill in vivo ................................................. 38 
3.1 Introduction .................. ... .. ............ .. ........... .. ...... ................ .... ........ .. ...... .... .. ..... 38 
3.2 Expression of peroxiredoxin III mRNA ....... .......... ........ .. ....................... .... ....... 41 
3.3 Specificity of prx III primers ... .... ... ... ...... ... ....... ........... ...... .......... ... ............. ... .. 42 
3.4 Determination of optimal primer concentrations ..... ...... ... ...... ....... ...... ...... ...... 47 
3. 5 Determination of average primer efficiency ..... ........ ........ ................................ 49 
3.6 Fold change in prx Ill mRNA ........................... ..... ... .... ..... ........ ................... ... .. 51 
3.7 Expression ofprx III protein ....... .................. .. ..... ............. .. .............. ..... ........... 54 
3.8 Chapter summary ......... .......... ...... ..... ...... ...... ..... ...... ............ ..... ........ .... ........ .. .. 60 
Chapter Four: Formation of complexes ........ ....................................................... 62 
4.1 introduction. ..... ..... .. ...... ............. .................. ... .................................... ......... ..... 62 
4.2 Detection of higher molecular weight complexes in MCF7 cells .... ....... ...... ... . 62 
4.3 Detection of higher molecular weight complexes in white blood cells ......... .... 65 
4.4 Chapter summary ....... .. .................................................... ...................... .... .... ... 69 
Chapter 5: Inactivation of peroxiredoxin Ill ... ........................................................ 70 
5. 1 Introduction. .. ........ .... ..... ......... .... ........... ... .......... ........... ... .............. .. .... .. .... ...... 70 
5.2 Oxidative stress and peroxiredoxin III over-oxidation ........ ............. ................ 72 
5. 3 Over-oxidation of peroxiredoxin III in response to doxorubicin exposure ..... . 7 4 
5.4 Chapter summary ....... ...... .. ... .......... ....... ........ ............ ........ .. .... .......... .............. . 76 
6.1 Overview ........ ..... ........ ........... ... .............................. ......... .... ... ........ .... ........ .. .... 77 
6.2 Summary of results ............... ... ....... .... .. ..... ... .... ...... ....... ... .. ...... .. ......... .............. 78 
6.3 Future research. .... ... .... ... ... .... ... .... ........ .............................. .......... ............. ....... 84 
6.4 Conclusion ..... ....... ... .......... ... ... ...... ..................... .. ...... ..... ........... ..... ................ . 87 
References ............................................ ........ ...................... .............................................. 89 
Appendix One: Bradford Protein Quantification Assay ............................................. 95 
Appendix Two: One-sample, two-sided t-test ............................................................... 96 
XI 
Appendix Three: Sample of data used to generate standard curves .......................... 97 
Appendix Four: Example of Coomassie-stained SDS-PAGE gel ............................... 98 
Appendix Five: a.-tubulin antibody ............................................................................... 99 
Appendix Six: Sample of data used to calculate fold change .................................... 100 
Appendix Seven: Identification of P-actin band ......................................................... 101 
Appendix Eight: Example of agarose gel electrophoresis results obtained during real 
time RT-PCR optimisation ........................................................................................... 102 
Appendix Nine: Example amplification curves obtained during real time RT-PCR 
experiments .................................................................................................................... 103 
Appendix Ten: Example of results obtained during real time RT-PCR experiments 
......................................................................................................................................... 104 
Appendix Eleven: Coomassie stained 2DE gel to confirm successful isoelectric 
focusing .......................................................................................................................... 105 
Appendix Twelve: Chromatogram from peroxiredoxin Ill DNA sequencing ........ 106 
Xll 
Chapter 1: Introduction 
1. 1 Cancer 
Cancer is a leading cause of death and disease in many (Ministry of Health , 2007). Cancer, 
or the development of tumours , appears to be the result of a number of genetic changes in a 
cell. Hanahan and Weinberg (2000) outlined six "hallmarks" of cancer - changes that are 
seen in most, if not all , tumours . 
The first is the ability of cells to mimic normal growth signals. Normal cells require signals 
from their environment to grow. Without these signals, normal cells do not proliferate. 
Cancer cells develop the ability to grow without these signals , through a number of 
mechanisms. Some cells appear to develop the ability to synthesise their own growth 
factors, while other cells over-express growth factor receptors allowing stronger responses 
to background levels of growth factor, or express mutant receptors which are constitutive ly 
active , mimicking constant stimulation with growth factor (Faivre and Lange, 2007). 
Cells must also develop insensitivity to the anti-growth signals rece ived from their 
environment. Similarly to growth factors , anti-growth signals are received by cell-surface 
receptors . If these cell-surface receptors are lost or mutated, cells become unresponsive to 
anti-growth signals. This in tum allows cells to grow when they otherwise would not. 
As well as being able to proliferate inappropriately, it appears that cells also need to be able 
to avoid programmed cell death (apoptosis) if a tumour is to develop . Sensors continually 
monitor both the intracellular and extracellular status for any signs of abnormality, such as 
DNA damage or hypoxia. Signals suggesting an abnormality or a lack of signals indicating 
the normal situation trigger apoptosis. For example, a major protein involved in sensing 
DNA damage and triggering apoptosis is p53 . Loss of p53 is seen in a large percentage of 
cancers and appears to represent an important mechanism for avoiding apoptosis (Harris, 
1996). 
Normal cells in culture appear to be able to double only 60 to 70 times, while tumour cells 
are able to double indefinitely (Hayflick, 1965). The ends of the chromosomes, called 
telomeres, appear to be responsible for this limit in the number of doublings a normal cell 
can undergo. Telomeres consist of many copies of a short repeat sequence. Due to the 
inability of the replication machinery to reach the ends of the chromosomes, 50- 100 base 
pairs (bp) are lost from the end of the telomeres at each cycle of replication. Eventually the 
telomeres become too short, chromosomes become unstable and cell death occurs (Counter 
et al. , 1992). Cancer cells however are able to prevent telomere shortening by up-regulating 
expression of telomerase, the telomere maintenance enzyme (Shay and Sacchetti , 1997). 
A large network of capillaries supplies oxygen and essential nutrients to all cells of the 
body; without this blood supply cells die. The same is true for cancer cells . Therefore if 
tumours are to continue to grow, new blood vessels are required . Not surprisingly, many 
tumours develop the ability to induce angiogenesis (the growth of new blood vessels). A 
number of changes in gene expression appear to be involved in the ability to induce 
angiogenesis however, these are not yet fully understood (Bouck et al. , 1996). 
Finally, many tumours eventually develop the ability to invade surrounding tissue and form 
tumours at new sites , a process known as metastasis . This is responsible for approximately 
90% of cancer deaths (Sporn, 1996). Once tumours metastasise, often the only practical 
treatment available is chemotherapy (Sauna et al., 2007) , a treatment which presents its 
own problems as will be discussed later in this chapter. 
The development of cancer is clearly a complicated process, involving numerous alterations 
of the genome and gene expression patterns. Not surprisingly, the treatment of cancer is 
also complicated. Currently a combination of surgery, chemotherapy, and in some cases 
radiotherapy is used to target cancer cells. There are numerous anti-cancer drugs available 
for use, and new drugs are continually being developed. Two drugs routinely used to treat a 
variety of tumours are doxorubicin (adriamycin), and the almost identical drug epirubicin. 
Doxorubicin ( dox) and epirubicin ( epi) differ only in the orientation of one hydroxyl group, 
which appears to be responsible for the slightly decreased cardiotoxicity of epirubicin 
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(Salvatorelli et al., 2006). Dox binds DNA by intercalating between base pairs, inhibiting 
both RNA synthesis and DNA replication. This prevents production of proteins and 
replication of cells (Blum and Carter, 1974). Dox also associates with the topoisomerase II-
DNA complex, inhibiting DNA re-ligation which results in the accumulation of double-
stranded DNA breaks (Lothstein et al., 200 I) . Finally, doxorubicin has been associated 
with an increase in the generation of reactive oxygen species (ROS) such as hydrogen 
peroxide (H20 2) , which in turn have been linked to the induction of apoptosis (Lothstein et 
al. , 2001 ). Epirubicin functions through the same mechanisms as doxorubicin (Salvatorelli 
et al. , 2006). 
Chemotherapy is usually administered in three week cycles, giving patients time to recover 
between doses . Optimal doses of anti-cancer drugs are designed to produce maximal death 
of cancer cells , without being toxic to the patient. However, the side-effects associated with 
anti-cancer drugs often prevent use of the optimal dose, or prevent patients from receiving 
all doses of chemotherapy, which reduces the effectiveness of the treatment. Individual 
variations in the rate of absorption, metabolism and excretion of anti-cancer drugs can also 
influence the efficacy of treatment (Ralph et al. , 2003). However, the ability of cells to 
develop resistance to anti-cancer drugs poses the biggest challenge to chemotherapy and the 
treatment of cancer. 
1.2 Mechanisms of drug resistance 
A number of mechanisms of drug resistance have been characterized. These mechanisms 
may be present before treatment, or develop as a response to chemotherapy, and usually 
involve up-regulation of resistance mechanisms or down-regulation of drug targets (Di 
Nicolantonio et al. , 2005). One of the most extensively studied mechanisms of drug 
resistance involves up-regulation of P-glycoprotein (P-gp). P-gp is expressed in several cell 
lines which are resistant to a number of different chemotherapeutic agents . P-gp is an ATP-
binding cassette (ABC) transporter protein found in the plasma membrane, and is capable 
of pumping drugs such as doxorubicin and epirubicin out of cells. P-gp expression has been 
shown to quickly increase in some patients in response to a variety of chemotherapeutic 
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drugs (Di Nicolantonio et al. , 2005). Increased expression of P-gp leads to increased efflux 
of drugs from the cells, reducing their ability to induce cell death. 
Changes that result in a decrease in the uptake of certain drugs may also play a role in the 
development of drug resistance. For example in the case of methotrexate, a toxic folate 
analog, resistance occurs through the mutation of one or both of the folate transporters 
(Gottesman, 2002). Reduced uptake decreases the effectiveness of a drug in mediating cell 
death and preventing cellular proliferation. 
Expression of topoisomerase II (topo II) appears to be down-regulated in response to a 
number of topo II-targeting drugs, including doxorubicin and epirubicin (Gottesman, 2002; 
Allen et al. , 2004) . Down-regulation of topo II results in decreased accumulation of double-
stranded DNA breaks. This allows DNA replication and transcription to occur, and prevents 
activation of cell death pathways usually activated in response to extensive DNA damage. 
Increased DNA repair has also been associated with the development of drug resistance, as 
increased repair of DNA damage allows cells to continue to proliferate (Gottesman, 2002). 
As with the development of cancer, the development of drug resistance appears to involve 
changes in the expression of multiple genes. While many mechanisms involved in drug 
resistance have been partially characterized, new mechanisms are continually being 
identified. Understanding the mechanisms involved in drug resistance is a vital step in the 
development of new and more effective treatments for cancer. 
1.3 Searching for new mechanisms of resistance 
As drug resistance plays such an important role in decreasing the effectiveness of anti-
cancer drugs, a great deal of work is being carried out to identify new target proteins 
involved in its development. Recent developments in both microarray technology and two-
dimensional electrophoresis have provided researchers with new ways to compare gene 
expression in drug-sensitive and drug-resistant cells. For example, complimentary DNA 
(cDNA) microarrays have been used to examine camptothecin resistance in glioblastoma 
cell lines (Morandi et al. , 2006), and two-dimensional electrophoresis has been used to 
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examme doxorubicin resistance m MCF7 breast cancer cells (Liu et al. , 2006). An 
unpublished study which used cDNA microarrays to examine changes in the expression 
patterns of cells in culture following doxorubicin exposure identified peroxiredoxin lil (prx 
lll) as one protein which is up-regulated in response to treatment with doxorubicin 
(Williams et al. , unpublished). In this study, MDAMB23 l , MCF 12A and MCF7 cells were 
exposed to 3 µM doxorubicin for 2 hours, 24 hours or 48 hours before RNA was extracted, 
first strand cDNA was synthesized and microarray experiments were performed. 
Expression of peroxiredoxin lil was found to be highest 24 hours after exposure to 
doxorubicin. MDAMB23 l , MCF12A and MCF7 cells showed 4-fold , 2.5-fold and 2-fold 
increases in peroxiredoxin llI expression respectively, 24 hours following treatment with 
doxorubicin . Prx Ill may therefore play a role in the development of resistance to 
doxorubicin, or epirubicin. 
1.4 Peroxiredoxins 
The peroxiredoxins (prxs) are a family of small , ubiquitously expressed peroxidases, which 
are highly conserved in both prokaryotes and eukaryotes (Kim et al. , 2005). There are six 
known human isoforms, which localize to different regions of the cell. Prx l and II are 
found in the cytoplasm and nucleus , and prx Ill localizes to mitochondria , while prx IV is 
found in the endoplasmic reticulum and extracellular space. Prx V exists in two forms , long 
and short. The long fom1 localizes to mitochondria while the short form is found in 
peroxisomes (Kinnula et al. , 2002) . Prx VI is found in the cytosol , mitochondria and 
peroxisomes (Knoops et al. , 1999). Based on the number of conserved cysteine residues 
present and the mechanism of activity, the peroxiredoxins have been divided into three 
separate classes - 2-cys (2-cysteine ) , atypical 2-cys and 1-cys ( 1-cysteine) peroxiredoxins. 
Peroxiredoxins I to IV are 2-cys proteins as they contain two conserved cysteine residues 
and form a homodimer during catalysis (Jeong et al. , 2006). Prx V is an atypical 2-cys 
peroxiredoxin as it forms an intramolecular rather than an intermolecular disulfide bond 
during catalysis (Jang et al. , 2006). Prx VI only contains one of the conserved cysteine 
residues, and is classed as a 1-cys peroxiredoxin, however other cysteine residues may play 
a role in catalysis (Kinnula et al. , 2002). 
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The mechanism of the 2-cys peroxiredoxins has been the most extensively examined, and 
an outline is presented in figure 1.1. H20 2 oxidises the conserved amino-terminal cysteine 
residue to produce an unstable cysteine-sulfinic acid intem1ediate. This unstable residue 
forms an intermolecular disulfide bond with the carboxyl terminal cysteine residue of a 
second prx molecule, to produce a head-to-tail homodimer. Thioredoxin then reduces the 
disulfide bond, to restore prx to an active state. Thioredoxin reductase then reduces 
thioredoxin at the expense of a molecule of nicotinamide adenine dinucleotide phosphate 
(NADPH) ( Seo et al., 2000; Chang et al., 2004). In the case of prx III, thioredoxin-2 the 
mitochondrial thioredoxin, is the electron donor, and thioredoxin reductase-2 restores active 
thioredoxin-2 (Chang et al., 2004). 
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Figure 1.1 Mechanism of H20 2 reduction by 2-cys peroxiredoxins 
H2O2 oxidises the conserved amino-tenninal cysteine residue to produce an unstable 
cysteine-sulfinic acid intennediate (SOH). This unstable residue fom1s an intramolecular 
disulfide bond with the carboxyl tem1inal cysteine residue of a second prx molecule, to 
produce a head-to-tail homodimer. Thioredoxin reduces the disulfide bond, to restore prx to 
an active state and thioredoxin reductase reduces thioredoxin at the expense of a molecule 
of nicotinamide adenine di nucleotide phosphate ( ADPH). 
1.5 Peroxiredoxins and Reactive Oxygen Species 
Reactive oxygen species such as H2O2 and the superoxide amon (02 -) are generated 
through the activity of the electron transport chain within mitochondria, and through 
cellular processes such as inflammation, the immune response and removal of foreign 
compounds (Apel and Hirt, 2004). The superoxide anion can be converted to H2O2 
spontaneously, or through the activity of a number of superoxide dismutases . H2O2 is 
removed from cells through the activity of a number of enzymes, including the 
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peroxiredoxins, catalase and glutathione peroxidases (Rhee et al., 2003). It is generally 
accepted that reactive oxygen species (ROS) such as H20 2 play an important role in 
oxidative damage and apoptosis. ROS are associated with damage to molecules such as 
DNA, proteins, carbohydrates and lipids (Rhee et al., 2003) . Furthermore, generation of 
H20 2 in response to apoptotic signals, such as those received in response to serious DNA 
damage, appears to lead to the release of cytochrome c into the cytoplasm, which in turn 
triggers the activation of caspases and eventually leads to cell death (Ragu et al. , 2007; 
Tsang et al., 2003) . 
A number of studies have shown that the peroxiredoxins are able to remove H20 2 from 
cells, and protect cells from H20 2-induced apoptosis when over-expressed. Bae et al. 
(2007) found that the normal breast cell line (MCF I 0A) transfected with prx I and II 
allowed cells to resist H20 2-induced cell death , when non-transfected cells could not. 
Depletion of prx Ill sensitized HeLa cells, a human cervical carcinoma cell line, to 
staurosporine- and TNF-a (tumour necrosis factor a)-induced apoptosis, and also resulted 
in increased intracellular H20 2 levels (Chang et al. , 2004) . 
ROS have also been implicated in a number of non-apoptotic signaling pathways. Signals 
from both platelet derived growth factor (PDGF) and epidermal growth factor (EGF) result 
in transient increases in intracellular H20 2 concentration. Inhibition of the increase in H20 2 
prevents protein tyrosine phosphorylation norn1ally seen in response to PDGF or EGF 
(Sundaresan et al., 1995; Bae et al., 1997). Stimulation of these cells with PDGF or EGF 
results in an increase in intracellular H20 2. Over-expression of prx I or II prevented this 
increase in H2O2 in a number of different cell lines (Kang et al. , 1998). Furthermore, 
extracellular H20 2 activates the transcription factor NFKB, which is then able to bind to 
NFKB binding sites to modulate expression of a number of genes . Over-expression of prx II 
in HeLa cells reduced NFKB binding to NFKB binding sites and reduced expression from a 
reporter construct under the control of NFKB binding sites (Kang et al. , 1998). Over-
expression of prx III has also been shown to result in decreased cell proliferation, providing 
further evidence in support of a role for peroxiredoxins in regulating or terminating signals 
from growth factors (Nonn et al. , 2003) . Therefore, ROS appear to be important in a 
8 
number of cellular signaling pathways, and peroxiredoxins are capable of terminating the 
signals generated by these pathways. 
1.6 Peroxiredoxins as molecular chaperones 
In 2002, Rabilloud et al. (2002) used two-dimensional electrophoresis and tandem mass 
spectrometry to examine the cellular response to oxidative stress. Their results showed that 
under oxidative stress a second, more acidic, form of several of the peroxiredoxins was 
present in cells. This more acidic form was most prominent for peroxiredoxin II, possibly 
because it is one of the most abundant peroxiredoxins in the Jurkat cells used in the study. 
These more acidic forms were not seen in response to other types of stress, therefore it is 
unlikely that this acidic form is associated solely with cell death . The more acidic form of 
prx appears to be caused by over-oxidation of the acidic site cysteine residue. The authors 
also report that cell death correlated with a decrease in the levels of normal prx under 
oxidative stress , suggesting that without functional peroxiredoxins a cell is more 
susceptible to oxidative stress-induced cell death . 
Moon et al. (2005) examined prx II structural changes in response to oxidative stress , and 
found that over-oxidised prx II forms much higher molecular weight complexes than the 
dimer formed by active prx II . To test whether the higher molecular weight complexes 
showed chaperone activity, the aggregation of several proteins in the presence and absence 
of prx II was measured. The first protein to be examined was citrate synthase (CS), a 
protein known to aggregate at high temperatures . In the presence of prx II , thermal 
aggregation was inhibited. The insulin p chain was also found to be protected from 
dithiothreitol-induced precipitation in the presence of prx II. Finally a-synuclein 
aggregation in response to oxidative stress was found to be inhibited by the presence of prx 
II. These higher molecular weight complexes were found to possess little peroxidase 
activity. In contrast, prx II dimers showed high levels of peroxidase activity, and did not 
exhibit any molecular chaperone activity. These results suggest that prx II is able to prevent 
aggregation and unfolding of a wide variety of proteins, rather than a small sub-set of 
proteins. Therefore, prx II may function as a peroxidase in dimer form and as a molecular 
chaperone, preventing protein unfolding and aggregation, when over-oxidised. In contrast 
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to the results presented by Rabilloud et al. (2002), Moon et al. (2005) report that the over-
oxidised forms of prx may increase resistance to H20 2-induced cell death . Kang et al., 
(2005) suggest that when H20 2 concentrations increase to higher than normal levels as a 
result of a "death signal" the prxs are over-oxidised to prevent termination of this signal. 
The prxs then take on the role of molecular chaperone, protecting proteins present in the 
cell. If the cell survives, the prxs may be reduced and return to functioning as peroxidases. 
Prx I also appears to act as a molecular chaperone after inactivation of its peroxidase 
activity. Jang et al. (2006) report that inactivation of prx I can occur through the 
phosphorylation of a threonine residue (Thr90). Prx I phosphorylated at Thr90, or mutated to 
aspartate at this residue to mimic phosphorylation, forms higher molecular weight 
complexes which exhibit negligible levels of peroxidase activity . Instead these complexes 
were found to possess chaperone activity, inhibiting thermal aggregation of malate 
dehydrogenase . Phosphorylation of Thr90 was found to be mediated by severa l cyclin-
dependent kinases in vitro. In vivo, prx I phosphorylation leve ls cycled in parallel with 
cyc lin-dependent kinase 2 (cdc2), suggesting that cdc2 is likely to play the most important 
role in prx I phosphorylation in vivo (Chang et al. , 2002). The authors suggest that 
phosphorylation of prx I is likely to occur after di sintegration of the nuclear envelope, and 
that the subsequent increase in H20 2 levels may play an important role in cell cycle 
progress10n. 
While there is evidence of molecular chaperone activity in higher molecular weight forms 
of prx I and II, formed following over-oxidation of the active cysteine residues , similar 
studies do not appear to have been carried out with other peroxiredoxins despite evidence 
for similar over-oxidation of these proteins. 
Recently Cao et al. (2007) examined the structures of oxidised and reduced prx III in vitro. 
The results suggest that reduced prx III spontaneously forms into a decameric ring 
structure, while oxidised prx Ill forms homodimers. Oxidised prx III was only found to 
form decameric rings at high protein concentrations (10 mg/mL), which may not be 
physiologically relevant. Whether these complexes also acted as molecular chaperones was 
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not examined. However, if the results obtained with the high molecular weight complexes 
formed by prx I and II apply to the structures formed by prx III these results suggest that 
prx III may have dual functions within the cell and that adopting the role of molecular 
chaperone may not be dependent on enzyme inactivation. Further work on the higher 
molecular weight structures formed by the 2-cys prxs clearly need to be carried out to 
determine the exact role these structures play within the normal cellular environment. 
1.7 Regeneration of active peroxiredoxin 
As peroxiredoxins appear to play an important role in signal transduction through the 
removal of H20 2 from cells, it was necessary to determine whether over-oxidised 
peroxiredoxin could be returned to its active form. Woo et al. (2003) used extracts from 
cells incubated with [351S-labelled amino acids, followed by washing and incubation with 
un-labelled amino acids, to examine whether re-generation of active prx I was due to de 
nova synthesis or reduction of the over-oxidised form. The results indicate that the active 
form of prx I can be regenerated through reduction of the over-oxidised form . Regeneration 
of other prx isoforms has since been shown. Sulfiredoxin (Srx I) , is a Saccharomyces 
cerevisiae protein encoded by a gene induced by high H20 2 levels. Biteau et al. (2003) 
discovered this protein was able to reduce the over-oxidised form of peroxiredoxins in 
yeast (a previously unknown role for Srx I). Following this discovery, the human sestrins 
Hi95 and PA26 were also found to reduce over-oxidised peroxiredoxins. Over-expression 
of Hi95 or PA26 was found to significantly increase the regeneration rate of active prx I 
(Budanov et al. , 2004) however further work is required to determine the mechanism of prx 
regeneration, and to identify proteins involved in regeneration of other prxs. 
1.8 Peroxiredoxins and disease 
Altered expression of sub-sets of the six peroxiredoxin isoforms has been linked to several 
diseases. Prx I expression appears to be enhanced in thyroid cancer (Yanagawa et al. , 
1999), and lung cancer (Chang et al., 2001 ). Prxs I, II and III appear to be over-expressed 
in breast cancer (Noh et al. , 2001). Prxs I, II, III, V and VI show increased expression 
compared to normal tissue in malignant mesothelioma (Kinnula et al., 2002). Furthermore, 
prxs I and II have been found to be over-expressed, and prx III down-regulated in both 
11 
Alzheimer's disease and Down ' s syndrome (Kim et al. , 2001; Sanchez-Font et al. , 2003). 
Prxs Ill to VI have been shown to be down-regulated in failing human myocardium 
(Brixius et al. , 2007), while prx V appears to be up-regulated in cells of the central nervous 
system in multiple sclerosis patients (Holley et al. , 2007). This list is far from exhaustive as 
changes in prx expression patterns are continually being associated with new diseases. 
Cancer cells are generally dividing rapidly, and as a result of constant stimulation by 
growth factors may have higher than normal intracellular H20 2 levels. The increased 
expression of peroxiredoxins in cancer cells may therefore be an attempt by cells to adapt 
to increased oxidative stress (Park et al. , 2006). The expression of different peroxiredoxins 
in different disease states suggests that while they all remove H20 2, the peroxiredoxins 
have distinct functions within the cell. 
1.9 Peroxiredoxin Ill 
Recent unpublished work suggested that peroxiredoxin Ill (AOP-1 , MER5 , PRDX3) may 
be up-regulated in cells exposed to doxorubicin. The exact role of prx lll within the cell 
remains to be elucidated, however experimental results suggest that prx lll plays a role in 
the regulation of H20 2 levels. Depletion of prx Ill from HeLa cells results in increased 
intracellular levels of H20 2, and sensitizes cells to induction of apoptosis by TNF-a (Chang 
et al., 2004). These cells showed increased rates of mitochondrial membrane potential 
collapse, cytochrome c release and caspase activation, which suggests that prx III plays a 
role in mitochondria-mediated apoptosis by regulating intracellular H20 2 levels . 
Furthermore, prx Ill (MER5) knockout mice showed increased susceptibility to 
lipopolysaccharide-induced oxidative stress, and 1.5 to 2.0 fold higher intracellular H20 2 
levels in macrophages compared to normal mice (Li et al., 2007). Lee et al. (2007) 
examined prx Ill expression in cultured human lens epithelial cells, and cultured whole 
lenses and found that prx Ill mRNA transcript levels significantly increased following 
exposure to H20 2 concentrations as low as 2 µM . These results further support the 
suggestion that prx III plays an important role in the removal of H20 2 in vivo . 
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There is some evidence that prx Ill plays a role in a number of signaling pathways within 
the cell. Nonn et al. (2003) reported reduced cell proliferation in cells over-expressing prx 
m, which may be due to increased removal of H20 2 produced during growth factor 
signaling. Yang et al. (2007) also report a role for prx III in proerythrocyte differentiation. 
Prx lII expression was found to fluctuate in human leukemia K562 cells following chemical 
induction of differentiation into erythrocytes. Furthermore, a K562 cell line over-expressing 
prx III was found to arrest in the G 1 phase of the cell cycle. These results suggest that prx 
III plays an important role in proerythrocyte differentiation, possibly by regulating 
intracellular H2O2. 
As both doxorubicin and epirubicin function to increase intracellular H2O2 levels (Lothstein 
et al. , 200 I; Tsang et al., 2003) this suggests a possible role for prx lil in the development 
of drug resistance. Increased expression of prx Ill following chemotherapy with dox or epi 
may make cells more tolerant to the increases in H2O2 caused by these drugs, increasing 
cell survival and reducing the effectiveness of chemotherapy. Such a role for prx III is 
supported by the observation that prx III over-expression in WEHI7 .2 mouse thymoma 
cells protected cells against apoptosis induced by the anti-cancer drug imexon, which also 
functions to increase intracellular H2O2 (Nonn et al. , 2003). 
As increased or reduced peroxiredoxin expression has been shown to have consequences 
for a number of cellular processes and signaling pathways, it is likely that the expression of 
prx lil and other peroxiredoxins is carefully regulated. Currently little is known about the 
regulation of prx III expression however recent work has identified some possible 
mechanisms of prx III regulation. Baker et al. (2007) found that prx III mRNA transcripts 
are up-regulated in the peripheral blood mononuclear cells (PBMC) of some patients 
treated with imexon. This up-regulation was seen within three hours of treatment; however 
sample sizes were very small. The authors also identified a putative antioxidant response 
element (ARE) in the prx III promoter which may play a role in this up-regulation. Specific 
binding of transcription factors to the ARE in the prx III promoter was not examined. 
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Prx Ill expression also appears to be partly regulated by c-Myc, and is required for Myc-
mediated transformation. Wonsey et al. (2002) examined prx Ill expression using a cell 
system where c-Myc was fused to the hormone binding domain of the estrogen receptor. 
This retains c-Myc in the cytoplasm until tamoxifen, an estrogen analog, is added. 
Cyclohexamide was used to inhibit protein synthesis. Prx Ill expression was found to 
increase following treatment with tamoxifen and cyclohexamide, which provides indirect 
support for a link to c-Myc. Chromatin immunoprecipitation experiments coupled with real 
time PCR identified a number of regions within the prx III gene which are bound by c-Myc 
following the addition of serum to serum-starved cells (Haggerty et al., 2003). Together, 
these results suggest that c-Myc directly regulates prx Ill expression. Logarithmically 
growing c-myc-null fibroblasts showed a reduction, but not a complete loss, in prx Ill 
expression (Wonsey et al. , 2002), suggesting that while c-Myc plays a role in regulating 
expression of prx Ill , other factors are likely to be involved. 
Rangwala et al. (2007) report a further mechanism of regulation of prx Ill in mouse 
embryonic fibroblasts . Peroxisome proliferator-activated receptor y coactivator-1 a (PGC-
1 a) appears to induce prx III expression in an estrogen-related receptor a (ERRa)-
dependent manner. ERRa regulates transcription of a number of genes by binding to 
estrogen response elements , however it does not bind estrogens. Prx lil mRNA expression 
also appears to be up-regulated in mouse uterine cells in response to estradiol. This up-
regulation appears to be dependent on the presence of the estrogen receptor (ER) (Deroo et 
al. , 2004), a ligand-activated transcription factor. Therefore, while prx lll expression 
appears to be ubiquitous, there may be tissue-specific differences in the levels of prx III 
expression. 
The regulation of prx III expression appears to be a complicated process, and remains to be 
fully elucidated. However, a number of studies suggest that regulation of prx III expression 
may be further complicated by regulation of the process of protein synthesis, or 
degradation. A number of studies have reported that prx III mRNA transcripts do not 
increase significantly, with increases above three-fold rarely being reported ( Lehtonen et 
al., 2005; Baker et al., 2007; Williams et al. , unpublished) . Instead, larger changes are seen 
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m protein express10n. Therefore, exammmg both prx llI mRNA and protein levels 1s 
important when studying and drug-induced changes in prx Ill expression. 
1.10 Research aims 
Prx Ill was identified as being up-regulated in response to doxorubicin treatment in 
cultured cells, which has led to the suggestion that prx llI may play a role in the 
development of resistance to doxorubicin and epirubicin. However, before such a role can 
be investigated further, the expression of prx Ill needs to be examined in patients 
undergoing chemotherapy with doxorubicin or epirubicin. White blood cells were collected 
from patients immediately before and three weeks after their first dose of chemotherapy 
with epirubicin. Samples were also collected from control subjects at three week intervals. 
Real time reverse transcription PCR was used to examine prx Ill mRNA expression, while 
sodium dodecylsulfate polyacrylamide gel electrophoresis (SOS-PAGE) coupled with 
western blotting was used to examine prx III protein levels. Furthermore, as prx lll has 
been shown to form higher molecular weight structures, native polyacrylamide gel 
electrophoresis (PAGE) coupled with western blotting was used to examine complex 
formation by prx lil in cultured MCF7 cells and white blood cells . Finally, prx Ill is known 
to be inactivated by over-oxidation of the active cysteine residue . Therefore two-
dimensional electrophoresis was used to examine over-oxidation of prx Ill in MCF7 cells 
following exposure to doxorubicin . 
The specific objectives of this work were: 
o To examme peroxiredoxin lll mRNA and protein expression m patients 
undergoing chemotherapy with epirubicin using real time RT-PCR and 
SOS-PAGE coupled with western blotting. 
o To examine peroxiredoxin III mRNA and protein expression m control 
subjects using real time RT-PCR and SOS-PAGE coupled with western 
blotting. 
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o To examme prx III complex formation in MCF7 cells in response to 
doxorubicin exposure, and the white blood cells of patients and control 
subjects using native-PAGE coupled with western blotting. 
o To examine over-oxidation of prx Ill in MCF7 cells following exposure to 
doxorubicin using two-dimensional electrophoresis coupled with western 
blotting. 
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